Traditional Chinese medicine composition for treating pelvic inflammation and preparation method thereof

Abstract

The invention provides a traditional Chinese medicine composition for treating pelvic inflammation and a preparation method thereof, and relates to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition for treating pelvic inflammation comprises the following Chinese herbal medicines in parts by weight: 10-20 parts of sargentgloryvine stem, 3-5 parts of radix rehmanniae, 5-10 parts of ricepaperplant pith, 3-6 parts of selfheal, 5-10 parts of radix paeoniae rubra, 3-5 parts of elecampane, 3-5 parts of hairyvein agrimony, 3-5 parts of felwort, 3-5 parts of motherwort and 3-5 parts of dandelion. The traditional Chinese medicine composition for treating the pelvic inflammation can be used for rapidly treating the acute pelvic inflammation, and the acute pelvic inflammation is not easy to relapse.

Description

Technical Field

[0001] The invention provides a traditional Chinese medicine composition for treating pelvic inflammatory disease and a preparation method thereof, belonging to the technical field of traditional Chinese medicines. Background Art

[0002] Pelvic inflammatory disease is an inflammation of the female internal reproductive organs and their surrounding connective tissues and pelvic peritoneum. Pelvic inflammatory disease includes acute pelvic inflammatory disease and chronic pelvic inflammatory disease. The continued development of acute pelvic inflammatory disease can cause diffuse peritonitis, sepsis, septic shock, and in severe cases, it can be life-threatening. If acute pelvic inflammatory disease is not effectively treated, it can turn into chronic pelvic inflammatory disease, which often does not heal over time and can recur.

[0003] Therefore, the key to effectively treat acute pelvic inflammatory disease is to avoid the formation of chronic pelvic inflammatory disease. Because acute pelvic inflammatory disease is rapid in onset, severe in condition, and dangerous in condition. Studies have shown that the cause of acute pelvic inflammatory disease is mainly heat toxicity, with dampness and stasis. Clinically, clearing away heat and detoxification is the main treatment, while removing dampness and removing stasis is the auxiliary treatment.

[0004] Currently, traditional Chinese medicine preparations for the treatment of acute pelvic inflammatory disease have the disadvantages of long treatment cycles and slow effects. Therefore, the development of a traditional Chinese medicine composition that is effective in treating acute pelvic inflammatory disease is a current research hotspot. Summary of the invention

[0005] In view of this, the object of the present invention is to provide a Chinese medicine composition for treating acute pelvic inflammatory disease and a preparation method thereof.

[0006] The present invention is achieved by adopting the following technical solutions:

[0007] A Chinese medicine composition for treating pelvic inflammatory disease, comprising the following Chinese herbal medicines in parts by weight:

[0008] 10-20 parts of red vine, 3-5 parts of raw rehmannia, 5-10 parts of tongcao, 3-6 parts of selfheal, 5-10 parts of red peony root, 3-5 parts of costusroot, 3-5 parts of agrimony, 3-5 parts of gentian, 3-5 parts of motherwort, and 3-5 parts of dandelion.

[0009] The preferred Chinese medicine composition for treating pelvic inflammatory disease of the present invention comprises the following Chinese herbal medicines in parts by weight:

[0010] 15-20 parts of red vine, 3-5 parts of raw rehmannia, 5-10 parts of tongcao, 3-6 parts of selfheal, 5-10 parts of red peony root, 3-5 parts of costusroot, 3-5 parts of agrimony, 3-5 parts of gentian, 3-5 parts of motherwort, and 3-5 parts of dandelion.

[0011] In one embodiment, the Chinese medicine composition for treating pelvic inflammatory disease of the present invention comprises the following Chinese herbal medicines in parts by weight:

[0012] 20 parts of Caulis Sargentodoxae, 4 parts of Radix Rehmanniae, 6 parts of Thunbergiae, 5 parts of Spica Prunellae, 8 parts of Red Peony Roots, 3 parts of Aucklandiae, 5 parts of Herba Agrimoniae, 5 parts of Gentianae, 5 parts of Leonurus, and 5 parts of Herba Taraxaci.

[0013] In one embodiment, the Chinese medicine composition for treating pelvic inflammatory disease of the present invention is characterized by comprising the following Chinese herbal medicines in parts by weight:

[0014] 18 parts of Caulis Sargentodoxae, 5 parts of Radix Rehmanniae, 10 parts of Herba Cyperi, 3 parts of Spica Prunellae, 10 parts of Radix Paeoniae Rubra, 5 parts of Radix Aucklandiae, 5 parts of Herba Agrimoniae, 3 parts of Radix Gentianae, 3 parts of Herba Leonuri, 5 parts of Herba Taraxaci.

[0015] In one embodiment, the Chinese medicine composition for treating pelvic inflammatory disease of the present invention is characterized by comprising the following Chinese herbal medicines in parts by weight:

[0016] 16 parts of red cauliflower, 3 parts of rehmannia, 5 parts of tongcao, 6 parts of prunella vulgaris, 5 parts of red peony root, 5 parts of costusroot, 3 parts of agrimony, 5 parts of gentian, 4 parts of motherwort, and 3 parts of dandelions.

[0017] In one embodiment, the Chinese medicine composition for treating pelvic inflammatory disease of the present invention is characterized by comprising the following Chinese herbal medicines in parts by weight:

[0018] 15 parts of Caulis Sargentodoxae, 4 parts of Radix Rehmanniae, 10 parts of Herba Cyperi, 4 parts of Spica Prunellae, 7 parts of Radix Paeoniae Rubra, 4 parts of Radix Aucklandiae, 4 parts of Herba Agrimoniae, 4 parts of Radix Gentianae, 4 parts of Herba Leonuri, and 4 parts of Herba Taraxaci.

[0019] The present invention also provides a medicine for treating pelvic inflammatory disease, which is specifically prepared by utilizing the above-mentioned Chinese medicine composition of the present invention.

[0020] The preparation method of the medicine for treating pelvic inflammatory disease of the present invention comprises the following steps:

[0021] Weigh red vine, raw rehmannia, tongcao, selfheal, red peony root, costusroot, agrimony, gentian, motherwort, and dandelion according to proportion, mix and grind into Chinese herbal medicine powder;

[0022] Add water to the Chinese herbal medicine powder and boil for 2 to 3 hours, then filter to obtain a filtrate and a filter residue;

[0023] The filter residue is added with water and boiled for a second time for 1-2 hours, and the two filtrates are combined after filtration;

[0024] The combined filtrate was concentrated to obtain a drug with a relative concentration of 1.10 to 1.13.

[0025] Compared with the prior art, the present invention has the following beneficial effects:

[0026] The invention provides a traditional Chinese medicine composition for treating pelvic inflammatory disease, which can quickly treat acute pelvic inflammatory disease and is not prone to recurrence. DETAILED DESCRIPTION

[0027] In order to make the purpose, technical scheme and advantages of the present invention clearer, the preferred embodiments of the present invention are further described in detail in conjunction with the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0028] Example 1

[0029] A medicine for treating pelvic inflammatory disease, the specific preparation method is as follows:

[0030] First, weigh the following Chinese herbal medicines by weight:

[0031] 20 parts of Caulis Sargentodoxae, 4 parts of Radix Rehmanniae, 6 parts of Thunbergiae, 5 parts of Spica Prunellae, 8 parts of Red Peony Roots, 3 parts of Aucklandiae, 5 parts of Herba Agrimoniae, 5 parts of Gentianae, 5 parts of Leonurus, and 5 parts of Herba Taraxaci.

[0032] Then the weighed Chinese herbal medicines are mixed and ground into Chinese herbal medicine powder;

[0033] The Chinese herbal medicine powder is added with water and boiled for 3 hours, and then filtered to obtain a filtrate and a filter residue;

[0034] The filter residue was added with water and boiled for a second time for 2 hours, and the two filtrates were combined after filtration;

[0035] The combined filtrates were concentrated to obtain a drug with a relative concentration of 1.12.

[0036] Example 2

[0037] A medicine for treating pelvic inflammatory disease, the specific preparation method is as follows:

[0038] First, weigh the following Chinese herbal medicines by weight:

[0039] 18 parts of Caulis Sargentodoxae, 5 parts of Radix Rehmanniae, 10 parts of Herba Cyperi, 3 parts of Spica Prunellae, 10 parts of Radix Paeoniae Rubra, 5 parts of Radix Aucklandiae, 5 parts of Herba Agrimoniae, 3 parts of Radix Gentianae, 3 parts of Herba Leonuri, 5 parts of Herba Taraxaci.

[0040] Then the weighed Chinese herbal medicines are mixed and ground into Chinese herbal medicine powder;

[0041] The Chinese herbal medicine powder is added with water and boiled for 3 hours, and then filtered to obtain a filtrate and a filter residue;

[0042] The filter residue was added with water and boiled for a second time for 2 hours, and the two filtrates were combined after filtration;

[0043] The combined filtrates were concentrated to obtain a drug with a relative concentration of 1.12.

[0044] Example 3

[0045] A medicine for treating pelvic inflammatory disease, the specific preparation method is as follows:

[0046] First, weigh the following Chinese herbal medicines by weight:

[0047] 16 parts of red cauliflower, 3 parts of rehmannia, 5 parts of tongcao, 6 parts of prunella vulgaris, 5 parts of red peony root, 5 parts of costusroot, 3 parts of agrimony, 5 parts of gentian, 4 parts of motherwort, and 3 parts of dandelions.

[0048] Then the weighed Chinese herbal medicines are mixed and ground into Chinese herbal medicine powder;

[0049] The Chinese herbal medicine powder is added with water and boiled for 3 hours, and then filtered to obtain a filtrate and a filter residue;

[0050] The filter residue was added with water and boiled for a second time for 2 hours, and the two filtrates were combined after filtration;

[0051] The combined filtrates were concentrated to obtain a drug with a relative concentration of 1.12.

[0052] Example 4

[0053] A medicine for treating pelvic inflammatory disease, the specific preparation method is as follows:

[0054] First, weigh the following Chinese herbal medicines by weight:

[0055] 15 parts of Caulis Sargentodoxae, 4 parts of Radix Rehmanniae, 10 parts of Herba Cyperi, 4 parts of Spica Prunellae, 7 parts of Radix Paeoniae Rubra, 4 parts of Radix Aucklandiae, 4 parts of Herba Agrimoniae, 4 parts of Radix Gentianae, 4 parts of Herba Leonuri, and 4 parts of Herba Taraxaci.

[0056] Then the weighed Chinese herbal medicines are mixed and ground into Chinese herbal medicine powder;

[0057] The Chinese herbal medicine powder is added with water and boiled for 3 hours, and then filtered to obtain a filtrate and a filter residue;

[0058] The filter residue was added with water and boiled for a second time for 2 hours, and the two filtrates were combined after filtration;

[0059] The combined filtrates were concentrated to obtain a drug with a relative concentration of 1.12.

[0060] 1. Animal Experiments

[0061] Female SD rats with a body weight of 190-230 g were selected. The rats were anesthetized with sodium pentobarbital (30 mg / kg) and fixed on the operating table in dorsal position. After routine abdominal disinfection, a 2 cm midline incision was made in the lower abdomen to expose the uterus. A No. 4 needle was carefully inserted at the bifurcation of the uterus, and 0.075 mL of compound phenol paste was slowly injected toward the ovary. After the injection, the abdomen was closed in layers, the surgical area was disinfected, and the modeling was completed.

[0062] The rats with successful modeling were randomly divided into high, medium and low dose groups of the drug in Example 1 of the present invention and a blank control group. The high, medium and low dose groups of the drug of the present invention were given vaginally at 10 mg / kg, 30 mg / kg and 50 mg / kg daily, respectively, and the blank control group was not treated in any way. The drug was given continuously for 7 days and fed normally. The animals were killed on the 8th day, the rat uterus was separated and taken out, and after weighing, the uterus was fixed with 10% formaldehyde solution, paraffin sections were made, HE staining was performed, and histological microscopy was performed.

[0063] Scoring Criteria

[0064] Cavity wall structure: each layer is clear as “-”; the glandular structure of the mucosal lamina propria is disordered or disappeared as “+”; the boundary between the muscular layer and the mucosal layer is unclear as “++”; the structure of the entire layer is unclear as “+++”.

[0065] Epithelial cells: single-layer columnar is “-”; flat cells or less than 1 / 3 of the epithelial cells are necrotic and detached is “+”; more than 1 / 3 is “++”; complete necrosis and disappearance is “+++”.

[0066] Endometrial congestion and edema: no congestion and edema is “-”; slight congestion and edema in the lamina propria is “+”; obvious congestion and edema is “++”; congestion and edema in the muscular layer and even the serosa is “+++”.

[0067] Chronic inflammatory cell infiltration: Count the number of lymphocytes and plasma cells in 4 unit areas at a micrometer grid of 10×20 times and take the average value. No inflammatory cells in each layer is "-"; only a large number of inflammatory cells are seen in the mucosal lamina propria is "+"; 20 to 30 inflammatory cells can also be seen in the muscularis, which is "++"; all layers are present, with a number greater than 30, which is "+++"

[0068] Fibroblasts: no proliferation is “-”; a small amount in the lamina propria is “+”; there are also more in the muscularis and the number is “++”; there are more than 30 cells in all layers and the number is “+++”.

[0069] Uterine cavity size: A reduction or expansion of the uterine cavity within 1 / 3 is a mild lesion, more than 1 / 3 to 2 / 3 is a moderate lesion, and more than 2 / 3 is a moderate lesion.

[0070] Each lesion severity is marked as +, ++, +++, ++++ from mild to severe, and no lesion is marked as "-", and the scores are 1, 2, 3, 4, and 0. All scores are accumulated and the average score of each group of animals is calculated. The higher the score, the more severe the inflammatory lesion.

[0071] Pathological results

[0072] The results showed that the high, medium and low dose groups of the drug all showed a decrease in uterine cavity adhesions. Among them, the medium dose group had significantly reduced endometrial epithelial degeneration, myometrial congestion and edema, inflammatory cell infiltration, and inflammatory response in the lamina propria and basal layer compared with the blank control group.

[0073] The results of the effect of the drug of the present invention on the degree of uterine inflammation in rats induced by phenol paste are shown in the table.

[0074] Table 1

[0075] Group Total score of inflammation High dose group 2.6±0.11 Medium dose group 2.3±0.08 Low dose group 3.1±0.28 Blank control group 6.2±0.75

[0076] 2. Clinical Trials

[0077] (1) Clinical data

[0078] One hundred patients with acute pelvic inflammatory disease, aged between 30 and 45 years old, were clinically observed and treated.

[0079] (2) Treatment methods

[0080] The drug prepared in Example 1 of the present invention was diluted with water at a ratio of 1:30 and then vaginally administered once a day for 7 days.

[0081] (3) Criteria for determining efficacy

[0082] Cured: All symptoms disappeared; major physical and chemical test indicators were normal.

[0083] Markedly effective: All symptoms are eliminated or major symptoms are eliminated; physical and chemical test indicators are basically normal.

[0084] Effective: The main symptoms basically disappeared; the main physical and chemical test indicators improved.

[0085] Ineffective: The main physical and chemical test indicators were unchanged compared with those before treatment.

[0086] (4) Clinical outcomes

[0087] 92 cases were clinically cured, 5 cases were markedly effective, 3 cases were effective, and 0 cases were ineffective.

[0088] The embodiments described above are part of the embodiments of the present invention, rather than all of the embodiments. The detailed description of the embodiments of the present invention is not intended to limit the scope of the invention claimed for protection, but merely represents selected embodiments of the present invention. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

Claims

1. A Chinese medicine composition for treating pelvic inflammatory disease, characterized in that: The invention comprises the following Chinese herbal medicines in parts by weight: 10-20 parts of red vine, 3-5 parts of raw rehmannia, 5-10 parts of tongcao, 3-6 parts of selfheal, 5-10 parts of red peony root, 3-5 parts of costusroot, 3-5 parts of agrimony, 3-5 parts of gentian, 3-5 parts of motherwort, and 3-5 parts of dandelion.

2. The Chinese medicine composition for treating pelvic inflammatory disease according to claim 1, characterized in that: The invention comprises the following Chinese herbal medicines in parts by weight: 15-20 parts of red vine, 3-5 parts of raw rehmannia, 5-10 parts of tongcao, 3-6 parts of selfheal, 5-10 parts of red peony root, 3-5 parts of costusroot, 3-5 parts of agrimony, 3-5 parts of gentian, 3-5 parts of motherwort, and 3-5 parts of dandelion.

3. The Chinese medicine composition for treating pelvic inflammatory disease according to claim 1, characterized in that: The invention comprises the following Chinese herbal medicines in parts by weight: 20 parts of Caulis Sargentodoxae, 4 parts of Radix Rehmanniae, 6 parts of Thunbergiae, 5 parts of Spica Prunellae, 8 parts of Red Peony Roots, 3 parts of Radix Aucklandiae, 5 parts of Herba Agrimoniae, 5 parts of Gentianae, 5 parts of Leonurus, and 5 parts of Herba Taraxaci.

4. The Chinese medicine composition for treating pelvic inflammatory disease according to claim 1, characterized in that: The invention comprises the following Chinese herbal medicines in parts by weight: 18 parts of Caulis Sargentodoxae, 5 parts of Radix Rehmanniae, 10 parts of Herba Cyperi, 3 parts of Spica Prunellae, 10 parts of Radix Paeoniae Rubra, 5 parts of Radix Aucklandiae, 5 parts of Herba Agrimoniae, 3 parts of Radix Gentianae, 3 parts of Herba Leonuri, 5 parts of Herba Taraxaci.

5. The Chinese medicine composition for treating pelvic inflammatory disease according to claim 1, characterized in that: The invention comprises the following Chinese herbal medicines in parts by weight: 16 parts of red cauliflower, 3 parts of rehmannia, 5 parts of tongcao, 6 parts of prunella vulgaris, 5 parts of red peony root, 5 parts of costusroot, 3 parts of agrimony, 5 parts of gentian, 4 parts of motherwort, and 3 parts of dandelions.

6. The Chinese medicine composition for treating pelvic inflammatory disease according to claim 1, characterized in that: The invention comprises the following Chinese herbal medicines in parts by weight: 15 parts of Caulis Sargentodoxae, 4 parts of Radix Rehmanniae, 10 parts of Herba Cyperi, 4 parts of Spica Prunellae, 7 parts of Radix Paeoniae Rubra, 4 parts of Radix Aucklandiae, 4 parts of Herba Agrimoniae, 4 parts of Gentianae, 4 parts of Herba Leonuri, 4 parts of Herba Taraxaci.

7. A drug for treating pelvic inflammatory disease, characterized in that: Prepared using the Chinese medicine composition according to any one of claims 1 to 6.

8. The method for preparing the drug for treating pelvic inflammatory disease according to claim 1, characterized in that: The following steps are involved: Weigh red vine, raw rehmannia, tongcao, selfheal, red peony root, costusroot, agrimony, gentian, motherwort, and dandelion according to proportion, mix and grind into Chinese herbal medicine powder; Add water to the Chinese herbal medicine powder and boil for 2 to 3 hours, then filter to obtain a filtrate and a filter residue; The filter residue is added with water and boiled for a second time for 1-2 hours, and the two filtrates are combined after filtration; The combined filtrate was concentrated to obtain a drug with a relative concentration of 1.10 to 1.13.